This review examines the current literature and clinical trials on ICIs and CAR-T cell therapies in GBM, focusing on its unique characteristics of the tumor microenvironment and detailing the PD-1/PD-L1, CTLA-4, and CAR-T pathways. This evidence concerns the gene CTLA4 and glioblastoma.